Literature DB >> 7917530

Determination of oestrogen receptors by enzyme immunoassay. Technical differences between laboratories and their consequences.

S Romain1, J L Formento, O Guirou, M Francoual, G Milano, P M Martin.   

Abstract

When multicentre breast cancer trials are performed, receptor analyses must be comparable both over time and in the participating laboratories. However, we show for the first time a high variability for the distribution of oestradiol receptor (ER) values measured by enzyme immunoassay (EIA) from 1987 to 1991. This variability could be explained by calibration changes in the immunoassay kits. We have also analysed the influence on ER-EIA levels of technical differences between laboratories apart from the assay itself. Many steps emerged as being critical, i.e. homogenisation buffer, homogenisation procedure and cytosol dilution. Finally, we show that addition of 4-monohydroxytamoxifen increases the apparent ER content measured by EIA in 92% of cytosols. Thus, many factors must be controlled to ensure high precision with ER-EIA assays. We have to be particularly cautious with the conformational changes that could occur during cytosol preparation and that could also pre-exist in the tumour samples. Quality controls of cytosol preparation are essential.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7917530     DOI: 10.1016/0959-8049(94)90285-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

1.  Improvement of quality control for steroid receptor measurements: analysis of distributions in more than 40000 primary breast cancers. French Study Group on Tissue and Molecular Biopathology.

Authors:  S Romain; F Spyratos; J Goussard; J L Formento; H Magdelénat
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Establishment and Fractionation of Metastatic Axillary Lymph Node Cell Suspension for Determination of Protein Expression Levels of Nuclear cFOS and Cytosolic TGFβ1 from Breast Cancer Patients.

Authors:  Vesna Ivanović; Nasta Dedović-Tanić; Zorka Milovanović; Bratislav Stojiljković; Miroslav Demajo; Vesna Mandušić
Journal:  Biol Proced Online       Date:  2022-06-04       Impact factor: 7.717

3.  Prognostic factors in 1,038 women with metastatic breast cancer.

Authors:  R Largillier; J-M Ferrero; J Doyen; J Barriere; M Namer; V Mari; A Courdi; J M Hannoun-Levi; F Ettore; I Birtwisle-Peyrottes; C Balu-Maestro; P Y Marcy; I Raoust; M Lallement; E Chamorey
Journal:  Ann Oncol       Date:  2008-07-17       Impact factor: 32.976

4.  Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients.

Authors:  J M Ferrero; M C Etienne; J L Formento; M Francoual; P Rostagno; I Peyrottes; F Ettore; E Teissier; P Leblanc-Talent; M Namer; G Milano
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.